EquityZen Growth Technology Fund LLC - Series 307
Raised
$313K
Investors
13
Min Invest
$10,000
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 307 is a Delaware-based pooled investment vehicle filed on 2018-10-17 by EquityZen Advisors and Assure Fund Management II, raising $313K from 13 investors under Rule 506(b) and 3(c)(1) exemptions with a $10K minimum investment. This is one of over 1,800 related entities within the EquityZen pre-IPO investment platform.
This pre-IPO fund vehicle employs the standard 506(b)/3(c)(1) exemption structure common to private market pooled funds, with a $10K minimum positioning it as accessible to accredited investors. The per-investor average of approximately $24K reflects the platform's retail-accessible secondary market model for private company shares.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Richard Thoms
Executive Officer · Salt Lake City, UT
Assure Fund Management II LLC
Director · Salt Lake City, UT
Shriram Bhashyam
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
